Sensex: 83,536.08 (-0.41%)

Nifty: 25,355.25 (-0.47%)

anubhai angaldas Securities Pvt. Ltd. Member: BSE - NSE - CDSL

Technology . Transparency . Trust

Contact Us
Apply For IPO

MARKET

IPO Synopsis
Gland Pharma Ltd
Registered Office: Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad - 500043, Telangana
Phone: 1
Email: 1
Website: 1
Initial public offer of 43196968 equity shares of face value of Re. 1 each ("equity shares") of Gland Pharma Limited ("Company" or "Issuer") for cash at a price of Rs.1500 Per equity share (including a share premium of Rs.1499 per equity share) aggregating Rs.6479.55 crores (The "Offer") comprising a fresh issue of 8,333,333 equity shares aggregating up to Rs. 1250 crores on (The "fresh issue") and an offer for sale of 34,863,635 equity shares, including 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd ("promoter selling shareholder") and 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Limited, 3,573,014 equity shares By Empower Discretionary Trust, and 1,874,500 equity shares by Nilay Discretionary Trust (collectively, the "other selling shareholders" and collectively With the promoter selling shareholder are referred to as the "selling shareholders", and such equity shares, the "offered shares") aggregating up to Rs. 5229.55 crores (the "offer for sale"). The offer shall constitute 26.46% of the post-offer paid-up equity share capital of the company. The face value of Equity shares is Re.1 each. The offer price is Rs.1500 per equity share and is 1500 times the face value of the Equity Shares. The Anchor Investor Offer Price is Rs.1500 per Equity Share.
Issue Money Payable On
Opens On Closes On Application Allotment
09-Nov-2020 11-Nov-2020 1,500.00 - 0.00 0.00 - 0.00
Cr. Lead Managers to the Issue
Project Cost 1,250.00
Project Financed through Current Offer 6,479.55
Post Issue Equity Share Capital 163.28
Issue Price 1,500.00
Projects
Funding incremental working capital requirements of the company
Funding capital expenditure requirements of the company
General corporate purposes
Promoted By
Fosun Pharma Indust. Pte. Ltd
Shanghai Fosun Pharma. Group
BSE
NSE
Registrar to the Issue
Attention Investor
As per CDSL communiqué Kindly update your Email ID, Mobile Number & Income Range in CDSL demat Account on or before 31st May 2021, Non Compliance Account will be INACTIVE after 31st May 2021. | Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors.  | "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account." | "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."    Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of Investors.